The timing he came in is at the same time as management and CEO increased their holdings with almost a million dollars from the board invested. Peers are trading at 110 million market caps on safety in humans so this is far from even being valued correctly at 50-60 cents
To say it’s speculative, it’s at a stage where it’s showing significant safety in humans and already de risked from NA-1 and shortly again from AGN on its mechanism of action in humans and passed 6 years of preclinical data. This is far from speculative. CEO has repeated twice big pharma want the cardiovascular indication as it’s the only drug in the world in what it does so that tells you that they have begun early discussions and the pattern seems to follow Aptoll which recieved a multi billion dollar license agreement with a 200 million upfront payment after phase 2a. Within 12-18 NYR will be in the same spot as Aptoll.
License agreement worth 2-3 billion like Aptoll and a 100-200 million dollar up front payment. Share price will be $2-$3 dollars a stock. 12-18 months to see that type of return on a license agreement pretty crazy. I don’t think this guy is stupid and neither is management. Insiders buying that’s what we want
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)